SUVENPHAR2022-01-012022-03-31in-bse-fin:OneOperatingExpenses01Member SUVENPHAR2022-01-012022-03-31in-bse-fin:OneOperatingExpenses02Member SUVENPHAR2022-01-012022-03-31in-bse-fin:OneOperatingExpenses03Member SUVENPHAR2022-01-012022-03-31in-bse-fin:FourOperatingExpenses01Member SUVENPHAR2022-01-012022-03-31in-bse-fin:FourOperatingExpenses02Member SUVENPHAR2022-01-012022-03-31in-bse-fin:FourOperatingExpenses03Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares SUVENPHAR 2021-04-01 2022-03-31 2022-05-02 INR Lakhs Yearly true Cash Flow Indirect Single segment Contract Development and Manufacturing 2022-01-01 2022-03-31 Audited Consolidated 3638472000.00 168712000.00 3807184000.00 1302781000.00 0.00 -199403000.00 311220000.00 21887000.00 104208000.00 653670000.00 2194363000.00 1612821000.00 0.00 1612821000.00 596454000.00 99687000.00 696141000.00 0.00 916680000.00 0.00 0.00 0.00 0.00 916680000.00 -1351000.00 915329000.00 0.00 0.00 0.00 0.00 254565000.00 1 3.60 3.60 0.00 0.00 3.60 3.60 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 9 May, 2022. The above results for the year ended 31st March 2022 has been audited and for the quarter ended 31st Mar2022 has been reviewed by the statutory auditors of the company 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 3) The consolidated financial results include the results of the wholly owned subsidiary Suven Pharma, Inc., USA. 4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. 5) The COVID-19 continuous to impact the business and research operations in India and our Wholly Owned Subsidiary, Suven Pharma, Inc., USA. Apart from the above the shortage or non- availability of vessels leading to delay in shipments, increase in transportation and distribution costs and timely non availability of materials with increase in materials costs are impacting our operations and profitability. 6) The other Income (Standalone figures) for the year-2021-22 includes an amount of Rs.15081.85 Lacs (Q3 Rs.3329.39 lacs & Q4 Rs.11752.46 lacs) pertaining to the Dividends received and Rs.1080.41 lacs pertaining to Gain on Investments on part disinvestment of Capital from our Subsidiary, Suven pharma, Inc. The Current tax for the year 2021-22 (Standalone figures) includes an amount of Rs.1676.21 lacs (Q3 Rs.491.72 Lacs & Q4 Rs.1184.49 Lacs) withholding tax paid on such Dividend by our subsidiary. 7) The Suven Pharma Inc., the WOS of our Company has divested its entire stake (25% amounting to $35.00 Mn) in M/s Rising Pharma Holdings, Inc., USA on 13th Dec, 2021. Accordingly, Rising Pharma Holdings, Inc., USA has ceased to be an associate company. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of $ 41.555 Mn and a stake valued at $15.803 Mn in Raisin Aggregators L.P. w.e.f 13th Dec'2021. Hence, the share of profits of associate has not been considered in the consolidated financial statements for the Quarter ended 31st Mar'2022. 8) The Board has declared an interim Dividend of Rs.1.00 per equity share (100% of Face value of Rs.1.00 each) and one-time special dividend of Rs. 1.00 per equity share (100% of Face value of 85.1.00), totalling to Rs. 2.00 per equity share (200% of Face value of Rs. 1.00 each) for the financial year 2021-22. 9) The corresponding previous period figures have been regrouped/reclassified where ever necessary. 10) Post approval of the Board in the meeting held on 5 April 2022, the company has completed acquisition of 100% stake in Casper Pharma Pvt Ltd. an SEZ company engaged in formulations business for USD 20.50 Mn and has become a wholly owned subsidiary of the Company w.e.f. 22 April 2022. Single segment 2021-04-01 2022-03-31 Audited Consolidated 13202221000.00 923803000.00 14126024000.00 4594564000.00 0.00 -603521000.00 1004839000.00 62310000.00 390971000.00 2412086000.00 7861249000.00 6264775000.00 0.00 6264775000.00 1904047000.00 233802000.00 2137849000.00 0.00 4126926000.00 0.00 0.00 0.00 411123000.00 4538049000.00 -7629000.00 4530420000.00 0.00 0.00 0.00 0.00 254565000.00 1 0.00 17.83 17.83 0.00 0.00 17.83 17.83 Manufacturing Expenses 443434000.00 Other Expense 188794000.00 R & D expenses 21442000.00 Manufacturing Expenses 1731886000.00 Other Expense 576655000.00 R & D expenses 103545000.00 62310000.00 -823369000.00 -1360880000.00 0.00 0.00 0.00 2697000.00 -108341000.00 0.00 232035000.00 0.00 36360000.00 0.00 382550000.00 0.00 4486000.00 22485000.00 54866000.00 0.00 44201000.00 0.00 686000.00 0.00 -82031000.00 -411123000.00 0.00 -6000.00 0.00 0.00 -1122200000.00 5142575000.00 0.00 0.00 0.00 1842573000.00 0.00 3300002000.00 0.00 -2440974000.00 0.00 0.00 0.00 0.00 0.00 0.00 6000.00 751867000.00 -2924255000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 686000.00 0.00 -126928000.00 0.00 -1361384000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -385971000.00 95973000.00 0.00 2533000.00 1018260000.00 62310000.00 0.00 240000.00 -1564807000.00 373811000.00 4000.00 373815000.00 71822000.00 445637000.00